Mersana Therapeutics
MRSN
MRSN was delisted on the 5th of January, 2026.
42 hedge funds and large institutions have $302M invested in Mersana Therapeutics in 2017 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 11 closing their positions.
118% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 11
45% more funds holding
Funds holding: 29 → 42 (+13)
28% more capital invested
Capital invested by funds: $236M → $302M (+$65.6M)
0.08% more ownership
Funds ownership: 3% → 3.08% (+0.08%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$5.42M |
| 2 |
BlackRock
New York
|
+$4.16M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$3.4M |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$2.01M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$3.12M |
| 2 |
SCM
Scopia Capital Management
New York
|
-$2.85M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.75M |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.51M |
| 5 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$800K |
MRSN Hedge Fund Activity: Q3 2017 in Review
42 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Mersana Therapeutics (MRSN) for Q3 2017, worth a combined $302M — up 28% from $236M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new MRSN positions and 11 closed out — a net gain of 13 holders — while 5 added to existing stakes and 7 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $5.42M. The largest seller was Rock Springs Capital Management, cutting an estimated $3.12M.
- 42 institutional investors held Mersana Therapeutics (MRSN) as of Q3 2017, up from 29 in Q2 2017.
- Funds reported $302M of Mersana Therapeutics stock for Q3 2017, up 28% quarter-over-quarter.
- 24 funds opened new Mersana Therapeutics positions in Q3 2017 and 11 closed out, a net change of +13 holders.
- The largest Mersana Therapeutics buyer in Q3 2017 was Wellington Management Group, an estimated $5.42M added.
- The largest Mersana Therapeutics seller in Q3 2017 was Rock Springs Capital Management, an estimated $3.12M sold.
Based on aggregated 13F filings for Q3 2017.